We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+2.01%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.42B
AUM Growth
+$183M
Cap. Flow
+$291M
Cap. Flow %
20.46%
Top 10 Hldgs %
37.91%
Holding
267
New
57
Increased
30
Reduced
117
Closed
58

Top Buys

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$19.5M
2
BCYC
Bicycle Therapeutics
BCYC
+$18.4M
3
INBX
Inhibrx, Inc. Common Stock
INBX
+$8.57M
4
IMTX icon
Immatics
IMTX
+$8.37M
5
AYLA
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
+$6.47M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$30.7M
2
ALEC icon
Alector
ALEC
+$14.1M
3
CRSP icon
CRISPR Therapeutics
CRSP
+$11.5M
4
ANVS icon
Annovis Bio
ANVS
+$8.86M
5
CGEM icon
Cullinan Oncology
CGEM
+$7.61M

Sector Composition

Rank Sector Weight
1 Healthcare 30.01%
2 Consumer Staples 0.24%
3 Technology 0.17%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CMMB
101
Chemomab Therapeutics
CMMB
$11.4M
$3.16M 0.22%
71,316
-1,318
-2% -$80.2K
VKTX icon
102
Viking Therapeutics
VKTX
$3.7B
$3.14M 0.22%
500,642
-24,112
-5% -$149K
CRSP icon
103
CRISPR Therapeutics
CRSP
$4.73B
$3.13M 0.22%
27,968
-91,743
-77% -$11.5M
TCDA
104
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.11M 0.22%
670,771
-104,523
-13% -$433K
DBVT
105
DBV Technologies
DBVT
$799M
$3.11M 0.22%
31,011
-1,262
-4% -$65.2K
ACET icon
106
Adicet Bio
ACET
$85.2M
$3.08M 0.22%
24,526
+16,679
+213% +$2.07M
ARKG icon
107
ARK Genomic Revolution ETF
ARKG
$1.57B
$3.06M 0.22%
40,961
– –
STSA
108
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$2.93M 0.21%
629,384
-14,672
-2% -$77.7K
FOLD
109
CALL
DELISTED
Amicus Therapeutics
FOLD
$2.87M 0.2%
+300,000
New +$3.07M
RNTX
110
Rein Therapeutics
RNTX
$63.1M
$2.82M 0.2%
138,179
-1,821
-1% -$39.9K
HZNP
111
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.81M 0.2%
25,661
-29,154
-53% -$3.03M
OCUL icon
112
Ocular Therapeutix
OCUL
$1.79B
$2.77M 0.2%
277,551
-142,022
-34% -$1.6M
STRO icon
113
Sutro Biopharma
STRO
$401M
$2.54M 0.18%
13,458
-78
-0.6% -$14.8K
RLAY icon
114
CALL
Relay Therapeutics
RLAY
$4.1B
$2.52M 0.18%
+80,000
New +$2.69M
RLAY icon
115
PUT
Relay Therapeutics
RLAY
$4.1B
$2.52M 0.18%
+80,000
New +$2.69M
LQDA icon
116
Liquidia Corp
LQDA
$7.48B
$2.44M 0.17%
884,893
-5,542
-0.6% -$14.4K
TAOX
117
Tao Synergies Inc
TAOX
$24.6M
$2.44M 0.17%
9,825
-2,175
-18% -$447K
SYBX
118
DELISTED
Synlogic
SYBX
$2.41M 0.17%
52,588
-3,969
-7% -$185K
KA
119
DELISTED
Kineta, Inc. Common Stock
KA
$2.36M 0.17%
32,680
+1,327
+4% +$94K
GOSS icon
120
CALL
Gossamer Bio
GOSS
$82.9M
$2.33M 0.16%
+185,400
New +$1.71M
INCY icon
121
Incyte
INCY
$24.2B
$2.25M 0.16%
32,666
-3,867
-11% -$294K
ELDN icon
122
Eledon Pharmaceuticals
ELDN
$261M
$2.13M 0.15%
344,578
-5,422
-2% -$37.9K
SVRA icon
123
Savara
SVRA
$1.12B
$2.13M 0.15%
1,539,691
-47,046
-3% -$63.5K
NKTR icon
124
CALL
Nektar Therapeutics
NKTR
$2.39B
$2.06M 0.15%
+7,653
New +$1.84M
EDIT icon
125
CALL
Editas Medicine
EDIT
$396M
$2.05M 0.14%
+50,000
New +$2.74M
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q3 2021 Portfolio in Review

As of Q3 2021, Ikarian Capital held 267 positions worth $1.42B, up 15% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Ikarian Capital deployed $291M of net new capital in Q3 2021, opening 57 new positions and adding to 30 existing holdings. Its largest new stake was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 44% a quarter earlier, followed by Consumer Staples and Technology.

On the sell side, the largest reduction was Biogen, an estimated $30.7M trimmed.

  • Ikarian Capital's largest Q3 2021 buy was Apellis Pharmaceuticals: 347,545 shares worth $11.5M.
  • Ikarian Capital added most to Inhibrx, Inc. Common Stock in Q3 2021, an estimated $8.57M increase.
  • Ikarian Capital's biggest Q3 2021 reduction was Biogen, cutting an estimated $30.7M.
  • Ikarian Capital fully exited Alector in Q3 2021, selling an estimated $14.1M.
  • Ikarian Capital's ten largest holdings make up 38% of its $1.42B portfolio in Q3 2021.
  • Ikarian Capital opened 57 new positions and closed 58 in Q3 2021.
  • Ikarian Capital's portfolio value rose 15% quarter-over-quarter to $1.42B.

Based on Ikarian Capital's 13F filing for Q3 2021, filed 15 Nov 2021.